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ABSTRACT
Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA 
in the circulation. Despite complicated collection methods and the requirement for 
technique-dependent platforms, it has generated substantial interest due, in part, 
to its potential to detect driver oncogenes such as epidermal growth factor receptor 
(EGFR) mutants in lung cancer. This technology is advancing rapidly and is being 
incorporated into numerous EGFR tyrosine kinase inhibitor (EGFR-TKI) development 
programs. It appears ready for integration into clinical care. Recent studies have 
demonstrated that biological fluids such as saliva and urine can also be used for 
detecting EGFR mutant DNA through application other user-friendly techniques. This 
review focuses on the clinical application of liquid biopsies to lung cancer genotyping, 
including EGFR and other targets of genotype-directed therapy and compares multiple 
platforms used for liquid biopsy.
LIQUID BIOPSY AND TISSUE BIOPSY 
IN LUNG CANCER
The term liquid biopsy was originally introduced to 
define circulating tumor cells (CTCs) but now includes 
circulating DNA and exosomes. Liquid biopsies are used 
for screening, to monitor treatment response, and to detect 
minimal residual disease after surgery. Liquid biopsies are 
considered important because genetic information from 
tumors can determine responses to certain treatments, 
such as epidermal growth factor receptor tyrosine kinase 
inhibitor (EGFR-TKI) in lung cancer. Lung cancer is a 
leading cause of cancer-related mortality, and 158,080 
lung cancer deaths are estimated for 2016 in the United 
States alone [1]. In recent years, advanced understanding 
of molecular abnormalities in lung cancer has helped 
define disease subsets and led to development of specific 
molecular targets in the presence of driver mutations, thus 
providing invaluable information for cancer treatment. 
Most research and clinical trials in the past decade focused 
on EGFR mutations and on the abnormal fusion of the 
echinoderm microtubule-associated protein-like 4 (EML4) 
protein with anaplastic lymphoma kinase (ALK), which 
have been inhibited successfully with EGFR-TKI and 
crizotinib, respectively. These targeted therapies have 
become key components in lung cancer treatment and 
have demonstrated superiority to chemotherapy in terms 
of overall response rate (ORR), progression-free survival 
(PFS), and quality of life in patients with untreated non-
small cell lung cancers (NSCLC) with sensitizing EGFR 
mutations [2-10]. However, these targeted therapies are 
based on mutation analysis via invasive examinations, 
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including biopsy or cytology specimens obtained from 
bronchoscopy, computed tomography (CT)-guided 
biopsy, surgical resection, or drainage from malignant 
pleural effusions. Compared with liquid biopsies, tissue 
biopsies have drawbacks that limit the detection of 
targeted mutations. First, in advanced or metastatic 
NSCLC, not all cases have accessible tissues and are 
therefore unavailable for tissue biopsy [11]. Moreover, a 
failure rate of 5% to 10% is observed when commercially 
available tumor genotyping techniques are used, despite 
sufficient tissue availability [12]. Second, biopsies may 
not fully reflect tumor heterogeneity. A recent study used 
direct sequencing to identify EGFR mutations in 180 pairs 
of lung adenocarcinoma samples before treatment and 
demonstrated that the discordance rates in metachronous 
(primary tumors with matched distant metastases) and 
synchronous (primary lesions detected at different times) 
settings were 14.3% and 9.1%, respectively. Additionally, 
the discordance rate in patients with multiple pulmonary 
nodules was significantly higher (24.4%) [13]. Liquid 
biopsies do not have these limitations because less 
invasive techniques are used, and liquid biopsies are 
capable of capturing tumor heterogeneity and dynamically 
monitoring tumor molecular changes. The different 
platforms used in detecting EGFR mutations are illustrated 
at Figure 1.
CIRCULATING TUMOR DNA
Circulating tumor DNA (ctDNA) is a subset of cell 
free DNA (cfDNA). The presence of small amounts of 
cfDNA in human plasma or serum was first discovered in 
1948. Cell free ctDNA was then identified in the blood of 
cancer patients in 1977, and was successfully genotyped 
as a tumor marker after 17 years [14]. The mechanisms 
of ctDNA origin include apoptosis, cancer cell necrosis, 
and extracellular vesicles (EVs) secreted from cancer 
cells. Unlike genomic DNA, ctDNA in plasma is highly 
fragmented and ranges from 180 bp to 1000 bp in size 
when it originates from apoptosis and approximately 
10,000 bp in tumor necrosis [10]. EVs are important in 
intercellular communication and contain large fragments 
( > 10 kb) of double-stranded DNA with mutated KRAS, 
p53, or EGFR gene sequences [15, 16]. However, ctDNA 
represents a small fraction ( < 1.0%) of total cfDNA, 
and conventional sequencing approaches such as Sanger 
sequencing or pyrosequencing are not sensitive enough 
to detect EGFR mutations in cfDNA. Nevertheless, PCR-
based diagnostics remain the key technique for detection 
and genotyping.
Many strategies have been developed to enhance 
the sensitivity of assays for detecting EGFR mutations. 
The amplification-refractory mutation system (ARMS)/
Scorpion assay is widely applied as a ctDNA-based assay 
to detect various EGFR mutations [17-20]. ARMS primers 
use specific probes with increased allelic specificity and 
are efficient in differentiating wild-type and mutant 
DNAs with a low level of background if the 3′ base is 
mismatched. Therefore, specific mutated sequences are 
selectively amplified with complete efficiency when the 
primer is fully matched.
In contrast, peptide nucleic acids (PNAs) have 
been applied for suppressing/blocking the wild-type PCR 
product. Both PNA-mediated PCR and peptide nucleic 
acid-locked nucleic acid (PNA-LNA) PCR clamps 
were designed to enhance PCR sensitivity. PNAs and 
LNAs are high-affinity DNA analogues that hybridize 
with complementary DNA, and PNA-DNA hybrids are 
more stable than cDNA-DNA hybrids [21]. Because 
PNA oligomers cannot function as primers during PCR 
reactions, they prevent amplification of wild-type DNA 
templates and improve both the sensitivity and the 
specificity in discriminating single base-pair mismatches. 
LNAs also have higher affinity to DNA and are designed 
to recognize mutant sequences. In conjunction with PNA 
clamp primers, EGFR mutations can be detected in the 
presence of 100-fold to 1,000-fold wild-type EGFR 
backgrounds [22]. 
An alternative strategy is to divide each sample 
into 20,000 or more discrete subunits before PCR 
amplification. For example, digital PCR and beads, 
emulsions, amplification, and magnetics (BEAM) can 
detect mutations in cfDNA at frequencies as low as 0.01% 
[23]. Digital PCR allows partitioning of input DNA into 
droplets and independent PCR in individual droplets 
[24]. After amplification, each droplet is subjected 
to fluorescence measurement to decrease the ratio of 
ctDNA/germinal DNA, resulting in increased sensitivity. 
BEAM technology combines emulsion digital PCR and 
flow cytometry [25]. Emulsion PCR amplification is 
incorporated with magnetic beads and flow cytometry for 
highly sensitive detection of known genetic mutations, 
even at very low copy numbers. Because DNA is 
covalently bound to magnetic microbeads via streptavidin-
biotin interaction, the PCR products generated in each 
droplet are affixed to microbeads at the end of the reaction, 
allowing subsequent separation and measurement of 
mutant variations by flow cytometry.
Both denaturing HPLC (DHPLC) and matrix-
assisted laser desorption ionization-time of flight 
(MALDI-TOF) were developed for analyzing DNA 
mutations under the umbrella of mass spectrometry 
(MS). For detecting EGFR mutations by DHPLC, PCR 
products are subjected to ion-pair-reversed-phase liquid 
chromatography. Compared with homoduplex sequences 
without EGFR mutation, partially denatured heteroduplex 
PCR products with EGFR mutant DNA move through 
the chromatography column at different rates [26, 27]. 
MALDI-TOF MS distinguishes EGFR mutation by 
the different masses of primer extension products. It is 
characterized by a combination of amplification, primer 
extension reaction, and transfer of the reaction product to 
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a chip containing specific matrix, thus allowing ctDNA 
detection with single-base specificity and sensitivity for a 
single DNA molecule [28, 29]. 
In contrast to techniques that detect known 
mutations, next-generation sequencing (NGS) can 
detect a subset of key genes and screen the entire tumor 
Figure 1: Sources of ctDNA and different platforms for detecting EGFR mutations in patients with lung cancer. A. 
Tumor cells constantly release CtDNA into circulation by a variety of mechanisms including cancer cell apoptosis and necrosis because 
of the rapid cellular turnover in tumors and extracellular vesicles (EVs) actively secreted by living tumor cells. PCR-based platforms 
are the most commonly used for detecting EGFR mutations, and non-PCR-based platforms such as EFIRM can be used to detect EGFR 
mutations. B. The conjugations between sample DNA, the detector probe, and the capture probe induce a reaction between the HRP-
labeled reporter probe and the TMB substrate and generate amperometric signals. C. The EGFR genotype can be determined in cDNA 
by several strategies, including amplifying target alleles (real-time PCR, ARMS/Scorpion assay), suppressing wild-type PCR products 
(PNA-LNA PCR clamp, peptide nucleic acid-locked nucleic acid PCR clamp), dividing each sample into 20,000 or more discrete subunits 
before amplification by use of BEAM and digital PCR. DHPLC and MALDI-TOF, under the umbrella of mass spectrometry, analyze 
DNA mutations after PCR amplification. NGS is uses DNA polymerase catalyzed incorporation of fluorescently labeled nucleotides across 
millions of fragments in a massively parallel fashion. D. Circulating tumor cells can be enriched by label-dependent and label-independent 
techniques. The label-dependent methods such as magnetic bead (CellSearch) and CTC chips, based on immunomagnetic assays target an 
antigen using an antibody conjugated to a magnetic bead. Filtration, Ficoll gradient, dielectrophoresis, and spiral microfluidics are based on 
the physical properties of tumor cells including size, density, electrical properties, and inertial-Dean drag force combinations, respectively, 
compared with erythrocytes and leukocytes. Combination methods including magnetic bead and filtration can be used to isolate CTCs more 
efficiently. E. Urine DNA derived from circulation was suggested to be mostly low-MW type. EGFR status was analyzed using a PCR 
method that amplifies short-target DNA fragments using kinetically favorable binding conditions for a wild-type blocking oligonucleotide, 
followed by massively parallel NGS. EFIRM: Electric field-induced release and measurement. HRP: Horseradish peroxidase; TMB: 
3,3’,5,5’-Tetramethylbenzidine; MT: Mutation; WT: wild type; ARMS: Amplification-refractory mutation system/Scorpion assay; PNA-
LNA PCR clamp: peptide nucleic acid-locked nucleic acid PCR clamp; BEAM: beads, emulsions, amplification and magnetics; DHPLC: 
denaturing high performance liquid chromatography; MALDI-TOF: matrix-assisted laser desorption ionization-time of flight; NGS: Next 
generation sequencing. 
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genetic code, with the potential to identify idiopathic 
resistant mechanisms. As with Sanger sequencing, NGS 
utilizes DNA polymerase to catalyze the incorporation 
of fluorescence-labeled nucleotides into a DNA template 
during sequential cycles of DNA synthesis. Instead 
of sequencing a single DNA fragment as in Sanger 
sequencing, NGS extends this process across millions of 
fragments in a massively parallel fashion [30]. Although 
the use of NGS has been reported for ctDNA-based 
EGFR mutation analysis [31, 32], its sensitivity of 2% 
allele frequencies for mutation detection in circulating 
DNA [33] is not as good as that of digital PCR. With 
the improvement of NGS platforms, including non-
overlapping integrated reads (NIOR) [34], adding barcode 
sequences by adaptor ligation, and a digital sequencing 
platform that enables single molecular sensitivity [35], 
the false positives decreased and sensitivity increased. 
Recently, cancer personalized profiling by deep 
sequencing (CAPP-Seq) combined optimized library 
preparation for low DNA input masses by use of a panel 
of biotinylated DNA oligonucleotides designed through 
bioinformatics analysis targeting the mutated regions 
of interest. CAPP-Seq is an ultra-sensitive technology 
designed to monitor tumor DNA. This method can detect 
one molecule of mutant DNA from 10,000 molecules 
of healthy DNA. Using this platform, they successfully 
detected ctDNA in 100% of stage II-IV NSCLC patients 
and in 50% of stage I patients, with 96% specificity for the 
mutant allele down to ~0.02% [36]. To further improve 
the CAPP-Seq performance, an integrated digital error 
suppression (iDES) was developed that combines in 
silico elimination of background artifacts with molecular 
barcoding for efficient cfDNA recovery. EGFR kinase 
domain mutations can be detected by this method with 
92% sensitivity and > 99.99% specificity at the variant 
level, and with 90% sensitivity and 96% specificity at the 
patient level [37]. However, NGS includes many complex 
processes, including template preparation, sequencing and 
imaging, and data analysis that determine its quality and 
its expense also limits its application in routine practice 
[38]. 
Other biological fluids, such as saliva and urine, 
are also used to detect EGFR mutations. Like blood, 
saliva contains a variety of biomolecules, such as 
DNA, mRNA, miRNA, proteins, and metabolites, that 
can be used as markers in predicting multiple cancers 
and systemic diseases [39]. Recently, we explored the 
clinical utility of saliva to detect EGFR mutations in 
NSCLC patients by developing an electric field-induced 
release and measurement (EFIRM) [40] composed of a 
polymer-based electrochemical chip with an array of 
16 bare gold electrode chips as sensors. Paired probes, 
including detector probes and capture probes, are designed 
specifically for L858R and Exon 19Del. Detector probes 
are labeled with fluorescein isothiocyanate, and capture 
probes are copolymerized with pyrrole onto the bare 
gold electrodes by applying a cyclic square-wave 
electric field. After polymerization, the samples mixed 
with detector probes are transferred onto electrodes for 
hybridization. After anti-fluorescein antibodies conjugated 
to horseradish peroxidase are added, interactions 
between the 3,3′,5,5′-tetramethylbenzidine substrate 
and horseradish peroxidase occur and the amperometric 
signal is measured. The total detection time is less than 10 
minutes and requires only 20 µL to 40 µL of the plasma 
or saliva sample. In a blinded test on saliva samples from 
40 late-stage NSCLC patients, the receiver operating 
characteristic analysis indicated that EFIRM detected exon 
19 deletions with an area under the curve (AUC) of 0.94 
and detected the L858R mutation with an AUC of 0.96. 
The platform was also validated in another pilot study 
from China [41]. 
Like saliva collection, urine collection is a 
noninvasive procedure requiring no special facility or 
equipment apart from sterile collection containers. Two 
distinct DNA sizes can be identified from urine, with 
high-molecular-weight (HMW) DNA from urinary tract 
cells and low-molecular-weight (LMW) DNA was from 
circulation [42]. Recently, these short-length, tumor-
derived DNA fragments were demonstrated to be filtered 
through the renal barrier and excreted into urine, and they 
can be used to detect KRAS in colon cancer [43]. Using a 
mutation enrichment PCR coupled with NGS detection, 
Reckamp et al [44] demonstrated that the sensitivity of 
the urine platform was 93% for T790M, 80% for L858R, 
and 83% for exon 19 deletions under a recommended 
volume of 90 mL to 100 mL of urine when the tissue 
result was used as a reference. At the American Society 
of Clinical Oncology (ASCO) Annual Meeting 2016, 
Wakelee et al [45] assessed EGFR status in tissue with 
a Therascreen EGFR test, in plasma by BEAM, and in 
urine by a quantitative short-footprint assay method using 
NGS. When tissue was used as the reference for EGFR 
genotyping, the positive percent agreement for T790M 
status between matched plasma and tissue was 81.5% (n = 
195) and that between matched urine and tissue was 83.8% 
(n = 136). The study showed that ctDNA EGFR mutation 
testing from urine is a novel way to non-invasively detect 
the T790M mutations missed in biopsies because of tumor 
heterogeneity or inadequate sample quality. The sensitivity 
of these platforms is summarized in Table 1.
CIRCULATING TUMOR CELLS
Numerous methods of enriching CTCs have been 
published and can be separated into label-dependent 
and label-independent strategies. The label-dependent 
method targets specific antigens on target cells by use 
of complementary molecules such as antibodies. The 
complementary molecules can be conjugated with 
Oncotarget18594www.impactjournals.com/oncotarget
magnetic beads or specific surfaces in a microfluidics 
platform. Among label-dependent techniques, 
immunomagnetic-based assays targeting EpCAM are 
most commonly used. Among the numerous EpCAM-
based CTC detection technologies, the semi-automated 
CellSearch® system is the most frequently used system and 
is the only one currently cleared by the U.S. Food and Drug 
Administration [46]. In addition to positively selecting 
target-cell populations, methods for negatively depleting 
off-target cells were also developed. Negative depletion 
against CD45-positive leukocytes is a preferred approach 
to isolate CTCs that lack adequate EpCAM protein 
expression. Enrichment selection methods utilizing anti-
EpCAM antibodies have evolved through the introduction 
of microfluidic chips, such as CTC-chip, CTC-iChip®, 
and the silicon-nanopillar chip, to facilitate operational 
reliability and isolation efficiency. In CTC-chips, whole 
blood flows through a chamber embedded with 80,000 
microposts coated with specific antibodies, which greatly 
increases the capture area [47]. The CTC-iChip employs 
continuous deterministic lateral displacement to remove 
nucleated cells from whole blood by size-based deflection 
utilizing a specially designed array. This inertial focusing, 
which lines the cells up and prepares them for precise 
magnetic separation and magnetophoresis, leading to 
sensitive separation in the immunomagnetic CTC isolation 
[48]. The silicon-nanopillar chip integrates ligand-receptor 
recognition, nanostructure amplification, and thermal 
responsive polymers, thus enabling highly efficient and 
selective cancer cell capture [49]
Label-independent enrichment methods separate 
CTCs based on physical rather than biological 
characteristics such as size, density, electrical properties, 
and inertial effect of flow. Filtering techniques utilize 
size differences and deformability characteristics of 
CTCs in comparison to blood cells, and the 3D parylene 
microfilter containing homogeneous pores enables direct 
CTC visualization/analysis on the filter [50]. The cell size 
in small-cell lung carcinoma (SCLC) and large-cell lung 
carcinoma (LCLC) ranges from an average of 7.2 µm to 
15 µm in diameter as measured from biopsies [51] but 
CTCs from clinical samples can be smaller. The most 
frequently applied filtration methods are performed by 
use of Screencell®Cyto and ISET® devices with track-
etched polycarbonate filter pores measuring 7.5 µm to 
8 µm in diameter and retain 85% to 100% of the tumor 
cells with only 0.1% of normal blood cells. Size-based 
filtration is convenient and is also applied to isolate 
lung cancer CTCs [52, 53], but its efficiency is limited 
because of false positivity arising from many leukocytes 
remaining on the membrane and smaller CTCs passing 
through it. This limitation is caused by the large range 
Table 1: Method or platform of CtDNA for detecting EGFR mutations and their associated sensitivity and application 
in lung cancer
Platform Sensitivity (% mutant DNA) Targeting mutation Reference
Mass spectrometry 1%–10% Known only Arcila et al [110], Brevet et al [111].
NGS 1%–10% Uchida et al [112]
Cobas, Therascreen, 
ARMS 1%–3% Known only
Mok et al [80], Pasquale et 
al [113], Goto et al [17]
Douillard et al [75]
Li et al [114]
Wang et al [19]
Kuang et al [115]
PNA–LNA PCR clamp 2% Known only Kim [116]Kim [117].
TAM-Seq 2% Known and new Forshew [33]
EFIRM 1%–2% Known only Wei et al [40]
Digital PCR <0.1% Known only Isobe et al [118]
BEAM <0.1% Taniguchi et al [119]
CAPP-Seq ~0.02% Known and new Newman et al [36]
iDES-enhanced CAPP-
Seq 0.0025% Known and new Newman et al [37]
Abbreviations: TAM-Seq: Tagged-amplicon deep sequencing
CAPP-Seq: Cancer personalized profiling by deep sequencing
iDES: Integrated digital error suppression-enhanced CAPP-Seq
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of CTC sizes in the same patient [54]. Traditional 
density-based gradient centrifugation methods using 
Percoll and Ficoll-Hypaque solutions separate the CTCs 
into the mononuclear cell fraction of blood, away from 
denser cells such as erythrocytes and granulocytes [55]. 
Various studies report that despite their popularity as 
inexpensive and reliable techniques, these methods have 
low CTC separation efficiency because the CTCs are still 
mixed with lymphocytes and monocytes. In addition, 
considerable numbers of tumor cells accumulate in the 
lower fraction instead of in the expected upper fraction 
after density gradient separation [54]. Thus, traditional 
density-based gradient centrifugation methods are not 
sufficient for precise CTC isolation. However, the robust 
operational benefit for primary CTC enrichment makes 
traditional density-based gradient centrifugation methods 
a good choice for combination with other label-free 
isolation methods, such as the OncoQuick® system and the 
ApoStream™ system [56]. By combining a porous barrier 
that allows erythrocytes and some leukocytes to pass 
while retaining CTCs with density-based centrifugation, 
the OncoQuick® system shows more effective enrichment 
[57]. However, elimination of contaminant monocytes is 
limited and the blood sample tends to mix with the gradient 
media if centrifugation is not performed immediately 
after applying the sample to the gradient media, thus 
restricting the usefulness of the samples if further 
enrichment techniques are not applied. Mammalian cells 
have a dielectric surface because they contain a variety of 
polarizable molecules, including proteins, peptides, and 
nucleic acids, and these dielectric properties are frequency 
dependent. Dielectrophoresis (DEP) applies a nonuniform 
electromagnetic field to the cell, and the cell responds 
to the DEP force by moving toward (positive DEP) or 
away from (negative DEP) the strong electromagnetic 
field [58]. Although low throughput limits its clinical 
utility as a device for isolating rare cells from blood, 
development of ApoStream™, which combines density 
gradient centrifugation and DEP, offers a continuous flow 
dielectrophoretic device for high throughput isolation 
and recovery of viable cancer cells from blood. Tran et al 
[56] used ApoStream™ to isolate CTCs from lung cancer 
and identified 12 EGFR mutations from 35 patients. 
Isolation and recovery of cancer cells from blood by use 
of ApoStream™ have been incorporated into numerous 
ongoing clinical trials. To improve throughput, a sustained 
Table 2: Multicenter diagnostic trials and meta-analysis of circulating free DNA diagnostic value for detecting EGFR 
mutation status in NSCLC
Trial (author) Sensitivity Specificity Platforms
Reck et al [72]
1162 patients
(ASSESS trial)
0.46
(0.388–0.534)
0.974
(0.962–0.983) ARMS, PNA-LNA
Han et al [73]
2,581 patients
(IGNITE trial)
0.48 in Asia 
(0.458–0.534)
0.30 in Russia
(0. 218–0.398)
0.972 in Asia
(0.960–0.981)
0.932 in Russia
(0.915–0.951)
Not mentioned
Jie et al [68]
20 studies
2012 cases
0.691
(0.569–0.790)
0.922
(0.878–0.951)
7ARMS, 3DHPLC, 2HRM, 2MEPCR, 
1 AS-APEX, 1 digital PCR, 1ME 
sequencing,1 MEL, 1 PNA, 1 PNA-LNA
Qie et al [69]
27 studies
3110 cases
0.620
(0.513–0.716)
0.959 
(0.929–0.977)
9ARMS, 3MEPCR, 2DHPLC, 2HRM, 2 
AS-APEX, 1 digital PCR, 1BEAMing,1 
Cobas, 1Sequenom,1 MEL, 1 PNA, 1 
PNA-LNA, 1 Inhibiting PCR-quenching, 
1Mutant-enriched sequencing
Mao et al [70] 
25 studies 
2605 case
0.61 
(0.50–0.71)
0.90
(0.85–0.94)
6ARMS, 5direct sequencing,
4MEPCR, 3DHPLC, 3 PNA-LNA, 1 
digital PCR, 1ME sequencing, 1WIP-
QP, 1pyrosequencing 
Qian et al [71]
27studies
3938cases
0.60 
(0.57–0.62)
0.94 
(0.93–0.95),
9ARMS, 3MEPCR, 2DHPLC, 2HRM, 2 
PNA, 2 PNA-LNA, 2 AS-PCR, 1 digital 
PCR, 1ME sequencing,1 MEL, 1 NGS, 
1 Deep sequencing
Abbreviations: HRM: High resolution melting analysis
ME-PCR: Mutant-enriched polymerase chain reaction
AS-APEX: Allele-specific arrayed primer extension reaction
MEL: Mutant-enriched liquid chip
WIP-QP: Wild inhibiting polymerase chain reaction (PCR) and quenched probe system
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3D lateral DEP system was developed by Cheng et al [59]. 
Throughput can be effectively increased by proportionally 
increasing channel length (maximum flow rate: ~2.4 mL 
h−1, linear velocity: ~4 mm s−1). Spiral microfluidics 
focuses the positions of larger CTCs apart from smaller 
blood cells based on a combination of inertial and Dean 
drag forces in a spiral microfluidic device, enabling 
rapid and continuous isolation of viable CTCs. At larger 
flow rates, particles focused closer to the wall and larger 
particles are stabilized nearer to the channel center 
because of the inertial flow effect. Moreover, addition of 
curvatures introduces a secondary cross-sectional flow 
field perpendicular to the primary flow direction (Dean 
flow). Thus, at the spiral channel outlet region, larger 
particles such as tumor cells are focused and aligned 
near the inner wall, whereas smaller particles such as 
neutrophils and red blood cells occupy a lateral position 
near the outer wall [60]. The rapid processing time and 
the ability to collect CTCs from a large patient blood 
volume allows this technique to be used in a broad range 
of potential applications. Khoo et al [61] used the spiral 
microchip to isolate CTCs for detecting EGFR mutation 
and ALK translocation. A combination of label-dependent 
and label-independent techniques is also practicable. 
Yamamoto et al [62] describe the use of a magnetic 
capture column for rapid and efficient capture at a high 
flow rate combined with addition into the filter at a low 
flow rate. The combination was shown to decrease the 
time required for cancer cell capture, and the recovery rate 
increased from 64.7% when the filter was used alone to 
80.7% in the combination method. The current strategies 
for CTC enrichment are summarized in Figure 1. 
The main advantage of using CTCs as markers is 
that they are potentially the floating phase of solid tumors, 
providing good samples for immunohistochemically 
staining and ex vivo studies. In addition to EGFR 
mutation-targeted therapy, multiple examples of 
genotype-directed therapy producing dramatic responses 
in molecular subtypes of lung cancer are emerging, 
including ALK rearrangements, ROS1 rearrangements, 
MET amplification, BRAF mutations, HER2 mutations, 
and RET rearrangements [63]. In contrast to the difficulty 
of detecting these mutations in ctDNA [64], ALK status 
of CTCs can be assessed by immunohistochemistry or 
fluorescence in situ hybridization after isolation and 
characterization [65]. The applications of CTCs also 
include ex vivo mechanistic studies of drug resistance by 
generating primary cultures from CTCs known as CTC-
derived xenografts. 
However, the applications and studies involving 
CTCs in lung cancer genotyping remain few compared 
with those that utilize CtDNA because of some inevitable 
limitations: the heterogeneous CTC number among 
different cancers and the dynamic changes in CTC 
characteristics at different stages of the disease. CTCs 
may be reliably detected in most patients with metastatic 
prostate, breast, and colorectal cancers by use of the FDA-
approved CellSearch technology, but this technology 
is limited in lung cancer because only approximately 
10% of patients with NSCLC show ≥5 CTC/7.5 mL for 
enumeration [66]. Moreover, aggressive tumor cells often 
undergo epithelial-mesenchymal transition (EMT), which 
results in loss of epithelial markers such as EpCAM. Even 
in the same patient, the expression of epithelial markers 
on CTCs can change dynamically, resulting in ineffective 
detection by an EpCAM antibody-based enrichment 
technique [67].
CLINICAL APPLICATION OF DETECTING 
EGFR MUTATIONS BY USE OF LIQUID 
BIOPSIES
Concordance with tissue biopsies
When liquid biopsy was first used to detect EGFR 
mutations in NSCLC patients, concordance with tissue 
biopsy was the key concern. Recently, four meta-analysis 
studies were conducted to investigate the diagnostic 
value of ctDNA compared with that of tumor tissues. 
Luo et al [68] identified 20 studies with a total of 2,012 
patients and demonstrated that the pooled sensitivity 
and specificity of cfDNA for detecting EGFR mutation 
status was 0.674 and 0.935, respectively. The methods 
used in these studies included direct sequencing, ARMS, 
denaturing high-performance liquid chromatography 
(DHPLC), peptide nucleic acid mediated polymerase 
chain reaction clamping, high-resolution melting (HRM), 
and digital PCR. Sub-group analyses showed that DHPLC 
and HRM had higher sensitivity than that of ARMS. Qiu 
et al [69] identified 27 eligible studies with a total of 3,110 
participants and performed a meta-analysis. The pooled 
sensitivity and specificity were 0.620 and 0.959 (95% CI, 
0.929 to 0.977), respectively. Overall analysis showed 
that ctDNA had high diagnostic accuracy and that ARMS 
was most useful for clinical practice. Mao et al [70] 
also demonstrated a similar result with a pooled overall 
sensitivity, specificity, and concordance rate of 0.61, 0.90, 
and 0.79, respectively, in a meta-analysis that included 
25 studies with 2,605 patients. Another study by Qian et 
al [71] showed similar sensitivity (0.60) and specificity 
(0.94), where the sensitivities of PNA-LNA PCR, AS-
PCR, and HRM were higher than those of ARMS and ME-
PCR, but the specificity of ARMS was the highest among 
the other tests. Two multicenter diagnostic studies (Europe 
and Japan in ASSESS, and Asia-Pacific and Russia in 
IGNITE) also evaluated the utility of ctDNA for EGFR 
mutation testing in a real-world setting. In the ASSESS 
trial, both tissue and plasma samples were available from 
1,162 patients with a sensitivity of 0.46 and a specificity of 
0.974, but the results were improved in the Therascreen® 
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subgroup [72]. In the IGNITE trial, both tissue and plasma 
available from 2,581 patients showed similar sensitivity of 
0.49.6 and specificity of 0.972, but included less data from 
Russian patients for unclarified reasons [73]. In summary, 
the specificity of different platforms is high (above 0.9), 
but the sensitivity is relatively low and varies from 0.4 
to 0.7. The diagnostic value and platforms used in these 
studies were summarized in Table 2.
PREDICTING PROGNOSIS AND 
DETECTING TKI-RESISTANT EGFR 
MUTATION
Because circulating DNA showed high concordance 
with tissue biopsies, some large clinical trials 
retrospectively investigated whether circulating EGFR-
mutated DNA could be used to predict prognosis. In the 
Iressa Pan-Asia Study (IPASS) [8], EGFR mutations 
were assessed by use of tumor tissue-derived DNA (n = 
91) and cfDNA from pretreatment serum samples (n = 
194). A significant interaction occurred between cfDNA 
EGFR mutation status and treatment for PFS (P = 0.045). 
PFS was significantly longer and objective response 
rate (ORR) was borderline higher in patients receiving 
gefitinib treatment than in those receiving carboplatin/
paclitaxel in the EGFR mutation-positive subgroup (PFS: 
hazard ratio [HR], 0.29; ORR: odds ratio [OR], 1.71; 
75.0% versus 63.6%; P = 0.40). However, the high rate 
of false negatives (56.9%) resulted in a slight numerical 
advantage in PFS and ORR for gefitinib over carboplatin/
paclitaxel in the EGFR mutation-negative subgroup [17]. 
The EURTAC trial demonstrated greater efficacy of 
erlotinib compared with chemotherapy for the first-line 
treatment of European patients with NSCLC harboring 
EGFR mutations in the tumor tissue [5]. EGFR mutations 
in ctDNA can be detected in 76 of 97 patients (78%), and 
the median OS was shorter in patients with the L858R 
mutation in ctDNA than in those with the exon 19 deletion 
(13.7 vs. 30.0 months; P  <  .001). Univariate analyses of 
patients with EGFR mutations in cfDNA identified the 
L858R mutation in tumor tissue or in cfDNA as a marker 
of shorter OS (hazard ratio, 2.70; P  <  .001) and PFS (HR, 
2.04 [95% CI, 1.20 to 3.48]; P  =  .008) [74]. Another phase 
IV trial, NCT01203917, included plasma samples from 
803 patients. The trial demonstrated that first-line gefitinib 
was effective and well tolerated in Caucasian patients with 
EGFR mutation-positive NSCLC. Median PFS was similar 
between mutation-positive tumors (9.7 m, 95% CI, 8.5 to 
11.0) and mutation-positive plasma (10.2 m, 95% CI, 8.5 
to 12.5) [75]. Another clinical trial was also designed to 
study whether plasma-based EGFR mutation analysis can 
predict tumor response. Bai et al [26] detected 81 EGFR 
mutations in 79 of 230 patient plasma samples (34.3%). 
Patients with EGFR mutations in plasma DNA had a PFS 
of 11.1 months (95% CI, 8.7 to 16.8) compared with 5.9 
months (95% CI, 2.1 to 9.7) in patients with no EGFR 
mutations (P = 0.044). The dynamic changes in EGFR-
mutated DNA detected by qualitative or quantitative 
analysis were also used to predict the treatment response 
to EGFR-TKI. Tseng et al [76] showed that failure to clear 
the plasma EGFR mutations after EGFR-TKI treatment 
for 10 weeks was an independent predictor of lower 
disease control rate, shorter PFS, and shorter OS. A similar 
result was reported by Lee et al [77], demonstrating that 
PFS was longer in patients with undetectable EGFR than 
in those with detectable EGFR mutations in blood after 
two months of treatment. The decrease rate in the semi-
quantitative index of EGFR mutant DNA in plasma has 
demonstrated a correlation with percent tumor shrinkage 
[78], and Yang et al [79] further reported that high EGFR-
mutated abundance in ctDNA showed better PFS than 
those with low EGFR-mutated abundance. Mok et al [80] 
further conducted a prospective analysis of blood-based 
EGFR mutation status assessment in the FASTACT-2 trial, 
which compared six cycles of gemcitabine/platinum plus 
sequential erlotinib or placebo. For patients with baseline 
EGFR mutations, median PFS was 13.1 months versus 6.0 
months for erlotinib therapy and placebo. For patients with 
baseline EGFR mutations, median PFS was 7.2 months 
versus 12.0 months and median OS was 18.2 months and 
31.9 months for positive EGFR mutation versus negative 
EGFR mutations by cycle 3, respectively (PFS: HR, 0.32; 
95% CI, 0.21 to 0.48, OS: HR, 0.51; 95% CI, 0.31 to 0.84) 
[80]. 
Although NSCLC patients with EGFR mutations 
experience ORRs of 60% to 70%, almost all patients 
develop resistance to therapy with an average PFS of 
9 months to 14 months. The mechanisms of acquired 
resistance to EGFR-TKIs include secondary mutations 
in EGFR, bypassed or alternative pathway activation, 
and histological/phenotypic transformation [81]. The 
most common cause of acquired resistance (60%) is 
the secondary mutation in EGFR in which methionine 
is substituted for threonine at position 790 (T790M) in 
exon 20. The third-generation EGFR inhibitors such as 
osimertinib (AZD9291), rociletinib (CO-1686), olmutinib 
(HM61713), EGF816, and ASP8273 are T790M mutant 
selective and EGFR wild-type sparing [82], leading to 
a need for noninvasive methods of T790M detection 
to guide the selection of therapy because of tumor 
heterogeneity and limited re-biopsies. Re-biopsy was 
not feasible in approximately 20% of cases because of 
difficult approaches, such as locations adjacent to central 
bronchi or vessels, miliary carcinomatosis [83], and the 
use of anticoagulants [84]. Moreover, both intratumoral 
and intertumoral heterogeneity undergo dynamic changes 
in relative populations of resistant clones over time as 
demonstrated in EGFR-mutant patients receiving more 
than one post-resistance biopsy and/or at autopsy [85, 
86]. Many studies have demonstrated the applicability of 
liquid biopsies in detecting T790M and its correlation with 
treatment response. T790M was reported for the first time 
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Table 3: The application of CtDNA in predicting prognosis and detecting TKI-resistance-EGFR mutations in lung 
cancer patients harboring EGFR mutations
Author Goal Treatment Case number Platform Conclusion
Goto et al [17]
Predicting prognosis 
by detecting EGFR 
sensitizing mutation
Gefitinib versus carboplatin/
paclitaxel (IPASS trial) 194 ARMS
Significantly longer 
in PFS but borderline 
longer in ORR at 
EGFRM (PFS: HR= 
0.29; P < 0.001; ORR: 
OR= 1.71; 75.0% 
versus 63.6%; P = 
0.40).
Karachaliou et al  [74]
Predicting prognosis by 
detecting L858R and 
Exon 19 Del
Tarceva versus first-line 
chemotherapy 76 PNA clamp
Median OS was shorter 
in L858R group than 
exon 19 deletion 
(13.7 vs 30.0 months; 
P < .001) but not in the 
multivariate analysis
Douillard et al
NCT01203917 [75]
Predicting prognosis 
by detecting EGFR 
sensitizing mutation
First- line gefitinib 803 ARMS
Similar Median PFS 
between mutation-
positive tumor (9.7 m, 
95% CI, 8.5–11.0) and 
plasma 1 (10.2 m,95% 
CI, 8.5–12.5) 
Bai et al [26]
Predicting prognosis by 
detecting L858R and 
Exon 19 Del
Gefitinib after failure of 
Chemotherapy 102 DHPLC
Longer PFS in EGFRM 
than EGFRw (11.1 
months, 95% CI, 8.7 
to 16.8 vs. 5.9 month, 
95% CI, 2.1 to 9.7) 
Tseng et al [76]
Predicting prognosis by 
detecting L858R and 
Exon 19 Del
First-line use of TKI 72 PNA–ZNA PCR clamp
Shorter PFS (HR: 1.97, 
95% CI: 1.33–2.91, 
P = 0.001) and OS 
(HR: 1.82 , 95% CI: 
1.04–3.18; P = 0.036) 
in presence of EGFRM 
after TKI treatment for 
10 weeks compared 
with those without 
EGFRM 
Yang et al [79]
Predicting prognosis 
by detecting EGFR 
sensitizing mutation 
and abundance
First-line or second-line use of 
TKI 73 DDPCR
1.Superior PFS (12.6 
vs. 6.7 months, P < 
0.001) and OS (35.6 
vs. 23.8 months,) in 
EGFRM 
2. High EGFRM 
abundance in ctDNA 
(> 5.15%) predicted 
better PFS (median, 
15.4 vs. 11.1 months, P 
= 0.021).
Mok et al (FASTACT-2 
study) [80]
Predicting prognosis 
by detecting EGFR 
sensitizing mutation
Six cycles of gemcitabine/
platinum plus sequential 
erlotinib or placebo
238 RT-PCR
For EGFRM patients 
with baseline; shorter 
PFS and OS in EGFRM 
(+) cfDNA versus 
EGFRM (−) cfDNA at 
cycle 3 patients (PFS, 
7.2 versus 12.0 months, 
HR, 0.32; P < 0.0001); 
(OS, 18.2 vs. 31.9 
months, HR, 0.51, P = 
0.0066).
Wang et al [88]
Predicting prognosis 
by detecting EGFR 
T790M
First-line or second-line use of 
TKI 135
DDPCR
ARMS
Pre-TKI treatment with 
T790M (+) showed 
inferior PFS (8.9 vs. 
12.1 months, P = 0.007) 
and overall survival 
(OS, 19.3 vs. 31.9 
months, P = 0.001) 
compared with those 
without T790M
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in 2005, but not until 2008 did Maheswaran et al [87] first 
detect the T790M mutation in circulating tumor cells from 
patients with EGFR mutations who had received tyrosine 
kinase inhibitors [87]. Wang et al [88] retrospectively 
investigated 135 patients with advanced NSCLC who 
showed PFS after EGFR-TKI for more than 6 months, 
for their status of EGFR-sensitive mutations and T790M 
mutation in matched pre-TKI and post-TKI plasma 
samples across multiple platforms. They demonstrated 
that D-PCR identified a higher frequency of T790M than 
ARMS did and that patients with pre-TKI T790M showed 
inferior PFS (8.9 months vs. 12.1 months, P =  0.007) and 
OS (19.3 months vs. 31.9 months, P  =  0.001) compared 
with those without T790M. Similar results have been 
reported by Zheng et al [89], who investigated the 
correlation between plasma EGFR T790M ctDNA status 
and clinical outcome in advanced NSCLC patients with 
acquired EGFR-TKI resistance. Among patients receiving 
TKI treatment as the second line or later, the T790M 
ctDNA-positive group showed significantly shorter OS 
than that in the negative group. Because third-generation 
EGFR inhibitors such as osimertinib (AZD9291), 
rociletinib (CO-1686), and olmutinib (HM61713) show 
impressive efficacy, especially in T790M-positive patients 
with a response rate of approximately 50% and a median 
PFS ranging from 9.6 months to 13.1 months [90-92], 
a clinical trial targeting lung cancer harboring T790M 
as well as surveying the application of liquid biopsy for 
T790M was conducted. Although rociletinib usage has 
been stopped in the clinic because updated data revealed 
lower response rates than those initially reported and 
because of a negative vote from the FDA’s Oncologic 
Drugs Advisory Committee, urine EGFR analyses can 
still be used to predict the treatment response in EGFR-
TKI resistant NSCLC from the Tiger X trial [45]. Urine 
testing resulted in a sensitivity of 81.1%, as EGFR T790M 
could be detected in 142 of 175 patients identified by 
tissue analysis. When 22 inadequate tissue biopsies were 
included in the reference sample, urine testing identified 
almost as many T790M-positive patients. The similar 
investigator-assessed ORR (25% to 32% in 500 mg bid 
and 33 to 40% in 625 mg bid) and the median duration of 
response (mDOR) (9 months in 500 mg bid and 6.7 to 8.0 
months in 625 mg bid) confirmed that urine testing can 
be used to predict treatment response to different doses 
of rociletinib as well as tissue samples [45]. Oxnard et al 
[93] performed both central tumor and plasma genotyping 
in 216 patients from 402 patients enrolled in the AURA 
Phase I escalation and expansion cohorts. When BEAM 
was used to analyze the plasma EGFR mutations, the 
sensitivity was 70% and the false-negative rate was 30% 
in plasma genotyping for T790M compared with tumor 
genotyping. PFS was also analyzed in patients classified 
by tumor and plasma genotyping. Tumor T790M positivity 
predicted a prolonged median PFS of 9.7 months, longer 
than that seen in tumor T790M-negative cases (P < 
Zheng et al [89]
Predicting prognosis 
by detecting EGFR 
T790M
TKI treatment at second-line 
or later 117 DDPCR
Patients with T790M 
(+) group had 
significantly shorter 
OS than the negative 
group (median OS: 
26.9 months versus NA, 
P = 0.0489).
Wakelee et al [45]
Predicting prognosis 
by detecting EGFR 
T790M in urine
Rociletinib treatment in 
patients with EGFRM NSCLC 
and acquired resistance to 
EGFR-TKIs (TIGER-X trial)
136 NGS
Objective response 
rate (ORR) and median 
duration of response 
(mDOR) are similar in 
T790M-positive urine 
(ORR, 32.0% in 500 
mg bid and 40.7% in 
625 mg bid; mDOR, 9 
months in 500 mg bid 
and 8 months in 625 
mg bid) and T790M-
positive tumor (ORR, 
25.0% in 500 mg bid 
and 39.4% in 625 mg 
bid; mDOR, 9 months 
in 500 mg bid and 7.9 
months in 625 mg bid)
Oxnard et al [93]
Predicting prognosis 
by detecting EGFR 
T790M
Osimertinib (AZD9291) 
treatment in patients with 
EGFRM NSCLC and acquired 
resistance to EGFR-TKIs 
(AURA Phase I)
216 NGS 
ORR and median PFS 
were similar in patients 
with T790M-positive 
plasma (ORR, 63%; 
PFS, 9.7 months) or 
T790M-positive tumor 
(ORR, 62%; PFS, 9.7 
months) results. 
Abbreviations: PFS: Progression free survival. ORR: Overall response rate. HR: Hazard ratio
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0.001). Although plasma T790M-positive status also 
predicts a prolonged PFS of 9.7 months, this survival is 
not significantly longer than that seen in plasma T790M-
negative cases (8.2 months, P = 0.188). In plasma T790M-
negative patients, tumor genotyping can distinguish 
patients with better and worse outcomes (tumor positive, 
16.5 months versus tumor negative, 2.8 months, P < 
0.0001). Among patients with plasma T790M positivity, 
those with tumor genotype showing positive T790M have 
a better outcome than those showing negative T790M in 
the tumor (9.3 months versus 4.3 months, P = 0.0002). 
This study suggests that patients can avoid a tumor biopsy 
for T790M genotyping if validated positive plasma 
T790M assays are available. 
Although third-generation TKI agents were 
developed to have potency against tumors bearing 
EGFR-activating mutations in the presence of the 
T790M mutation, acquired resistance was developed 
with preliminary PFS estimates of ~10 months in 
T790M-mutated patients [91, 92]. By performing next-
generation sequencing of cfDNA from seven patients who 
developed acquired resistance to AZD9291, Thress et al 
[94] identified the acquired EGFR C797S mutation in 
one patient and confirmed the role of C797S in mediating 
resistance to AZD9291 in a constructed mutant EGFR 
cell line. In two cases, tumor biopsies were available and 
the acquired C797S mutation was confirmed by targeted 
NGS because it was not detected in pretreatment tumors. 
Serial ddPCR profiling was performed on 15 subjects 
with advanced EGFR-mutant NSCLC before treatment 
and after acquired resistance to AZD9291. Pretreatment 
plasma ddPCR detected EGFR T790M mutations in 15 
subjects and C797S mutations in none of the subjects. 
Upon developing AZD9291 resistance, six subjects 
acquired the C797S mutation, five subjects maintained 
the T790M mutation but did not acquire the C797S 
mutation, and four subjects lost the T790M mutation 
despite the presence of the underlying EGFR-activating 
mutation. This study demonstrated the application of NGS 
to exploring novel mechanisms of acquired resistance 
to third-generation EGFR-TKI by sequence analysis of 
cfDNA. The studies that applied ctDNA to predicting 
prognosis and to detecting TKI-resistant EGFR mutations 
in lung cancer are summarized in Table 3
LIQUID BIOPSY FOR LUNG CANCER 
GENOTYPING OTHER THAN EGFR 
MUTATION
Although ctDNA and CTCs have been broadly 
investigated for the correlation with tumor genotyping 
for EGFR mutation, their application in detecting other 
targets of genotype-directed therapy, including ALK 
gene rearrangements, ROS1 gene rearrangements, MET 
gene amplification, BRAF gene mutations, HER2 gene 
mutations, and RET gene rearrangements, remains limited. 
These mutations can be assessed by isolating CTCs 
and detection using fluorescence in situ hybridization 
or immunohistochemistry because specific antibodies 
and probes targeting these molecules are commercially 
available [65, 95-102]. Recently, EML4-ALK fusion 
[36, 98] and unreported fusions involving ROS1 [36] 
were identified from plasma DNA by use of NGS 
platforms such as personalized cancer profiling by deep 
sequencing (CAPP-Seq). CAPP-Seq ctDNA analysis was 
also employed to investigate tumor heterogeneity and 
the associated mechanism of resistance to rociletinib. 
Chabon et al [103] identified one or more putative 
resistance mechanisms in 28 of 43 patients by serially 
collecting plasma before and after rociletinib therapy 
and demonstrated that MET copy-number gain was 
the most frequent mechanism in contrast to the most 
frequent C797S mutation that contributes to AZD9291 
resistance [94]. Moreover, pre-existing copy-number 
gains in MET, ERBB2, and EGFR were significantly more 
common in patients with innate resistance. These studies 
underscore the potential of NGS to detect the uncommon 
drug-sensitive mutations and the alternative pathways 
contributing to EGFR-TKI resistance via ctDNA.
GOLD STANDARD FOR DETECTING 
EGFR MUTATIONS AND ACQUIRED EGFR 
MUTATIONS AFTER RESISTANCE TO 
EGFR-TKI
In September 2014, the Committee for Medicinal 
Products for Human Use at the European Medicines 
Agency approved the use of ctDNA to assess the status of 
EGFR mutations when selecting EGFR-TKIs for patients 
in whom obtaining a tumor sample is not an option 
[104]. This update is applicable to all European Union 
member countries and will benefit patients who have 
locally advanced or metastatic NSCLC without available 
or evaluable tumor samples for EGFR mutation analysis. 
On June 1, 2016, the U. S. Food and Drug Administration 
approved the Cobas EGFR Mutation Test v2 (Roche 
Molecular Systems, Inc.), which uses plasma specimens 
as a companion diagnostic test for detecting exon 19 
deletions or exon 21 (L858R) substitution mutations in 
EGFR to identify patients with metastatic NSCLC who 
are eligible for erlotinib therapy [105]. Based on a meta-
analysis and other large clinical trials that demonstrate 
significantly longer PFS and higher ORR with EGFR-TKI 
than that in chemotherapy in the ctDNA EGFR mutation-
positive subgroup [17, 70], the use of ctDNA to guide 
EGFR-TKI treatment is reasonable when tumor samples 
are not eligible for EGFR mutation assay. 
Among patients who developed resistance to first 
line EGFR-TKI, many are too weak for re-biopsy, and a 
wide heterogeneity in resistance mechanisms may require 
its own therapeutic strategy [85, 106]. Therefore, liquid 
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biopsies may compensate for the limitations of tissue 
biopsies. Liquid biopsies use less invasive techniques and 
are capable of capturing tumor heterogeneity. Although 
Oxnard et al [93] proposed a paradigm where plasma 
genotyping is used as a screening test for T790M, before 
performing an EGFR resistance biopsy, the high false-
positive rate (30%) in plasma DNA and the outcomes 
of these patients depended on tumor genotyping. This 
dependence caused clinicians to become concerned 
about whether positive plasma DNA can be used to guide 
third-generation TKI use for patient developing drug 
resistance. In a recent update, the consensus statement on 
optimizing the management of EGFR mutation-positive 
NSCLC is that tissue-based molecular analysis remains 
the gold standard for establishing the initial diagnosis, as 
well as for evaluation of TKI resistance [107]. Recently, 
Sundaresan et al [108] compared the T790M genotype 
from tumor biopsies with an analysis of simultaneously 
collected CTCs and ctDNA. T790M genotypes were 
successfully obtained in 30 tumor biopsies (75%), 28 CTC 
samples (70%), and 32 ctDNA samples (80%). Although 
CTC-based and ctDNA-based genotyping failed to detect 
T790M in 20% to 30% of all cases, both assays together 
enabled genotyping in all patients with available blood 
samples and identified the T790M mutation in 14 patients 
(35%) in whom the concurrent tumor biopsy was negative 
or indeterminate. The finding was compatible with that of 
Oxnard et al [93, 109], wherein cases that were T790M 
negative in the tumor but were T790M positive in the 
plasma were further studied by use of orthogonal plasma 
genotyping assays such as ddPCR or Cobas®, and 78% 
of these cases could be confirmed as positive. Therefore, 
liquid biopsies can compensate for tumor biopsies because 
individual tumor biopsies alone provide an incomplete 
window into the heterogeneous nature of acquired drug 
resistance. Only their correlation with the clinical response 
to third-generation EGFR inhibitors may ultimately 
provide a true “gold standard” for T790M genotyping. The 
suggested paradigm for the use of plasma genotyping to 
complement tissue genotyping is summarized in Figure 2.
CHALLENGES OF LIQUID BIOPSY 
GENOTYPING ON THE PATH TO 
CLINICAL UTILITY
Though remarkable progress in the use of liquid 
biopsy has been made in recent years, several challenges 
remain to be overcome for its application in clinical 
routine practice of lung cancer. Many studies have 
aimed to detect and/or characterize CTCs or ctDNA in 
lung cancer patients; the question is which of these two 
approaches will become a better platform for managing 
these patients in the era of precision medicine. It seems 
as though more scientific studies exist supporting the 
use of ctDNA for profiling and characterization of lung 
Figure 2: A. The suggested paradigm for using plasma genotyping in clinical utility. For NSCLC patients when tumor samples are 
not eligible for EGFR mutation assay or the result of EGFR genotyping is inclusive at initial diagnosis, ctDNA can be used to complement 
tissue biopsy guiding EGFR-TKI treatment. B. Among patients who developed resistance to first-line EGFR-TKI, liquid biopsies can 
compensate tumor biopsies because tumor biopsies themselves provide an incomplete window into the heterogeneous nature of acquired 
drug resistance.
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tumor molecular alterations as well as for monitoring 
therapies and identifying mutations associated with 
acquired drug resistance. The most important issue is that 
plasma samples can be collected and analyzed without 
requiring prior enrichment, and there is no need to isolate 
a rare cell population. Compared to other cancers such as 
prostate and breast cancer, the number of CTCs in lung 
cancer is relatively low [105]. However, one important 
limitation of ctDNA is that in situ and morphological 
analyses using FISH and ICC (including ALK or ROS1 
status) cannot be performed with ctDNA. Though the 
combination of CTC and CtDNA has been applied in 
detecting T790M [108], the application of these two 
platforms together in lung cancer genotyping including 
EGFR, ALK, ROS, and MET amplification remained 
limited. The major problem is that there are many diverse 
techniques in each platform, and standardization is more 
complicated and requires more effort. Second, though the 
newly developed ctDNA platforms such as digital PCR, 
BEAMing, and advanced NGS platform showed higher 
sensitivity compared to conventional PCR-based platforms 
such as the Cobas EGFR kit and TheraScreen® EGFR 
plasma PCR kit, which were approved by FDA, Europe 
and China respectively (Table 1), the specificity of these 
platforms was relatively low [93]. More effort should be 
expended on optimizing these diverse technologies of 
ctDNA analysis and standardizing different platforms, 
and appropriate analytical and clinical validity needs to be 
demonstrated to control the pre-analytic phase and obtain 
robust and reproducible results. Finally, no randomized 
controlled trial demonstrates that liquid biopsy can be used 
to guide treatment strategy or compliment tissue biopsy. 
Critical clinical standards need to be established, and well-
designed and sufficiently powered multicenter clinical 
trials involving large cohorts of patients and controls are 
required to validate ctDNA as clinical tools. In addition, 
activation of alternative pathways such as epithelial 
mesenchymal transition or histologic transformation to 
small cell carcinoma, which also mediate resistance to 
EGFR TKI, cannot be detected by the currently available 
liquid biopsy platforms. Therefore, tissue biopsy cannot 
be replaced by liquid biopsy for diagnosis and treatment in 
advanced NSCLC but the combination of tissue and liquid 
biopsy will offer additional information that will help 
to treat lung cancer patients better in the view of tumor 
heterogeneity and predicting treatment response.
CONCLUSIONS
The above studies regarding liquid biopsies 
underscore their potential utility in lung cancer 
genotyping. With the paradigm shift brought by liquid 
biopsies in lung cancer treatment, additional qualifications 
combining clinical pathology, molecular pathology, and 
molecular biology will be required in the field of precision 
medicine. Changes in practice in oncology caused by 
judicious use of liquid biopsy potentially improve patient 
outcomes by expediting treatment decisions, predicting 
treatment response, and anticipating tumor relapses that 
are not yet visible on imaging.
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